Dual utilization of an acceptor/donor splice site governs the alternative splicing of the IRF-3 gene

Alla Y. Karpova, Peter M. Howley, and Lucienne V. Ronco

Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115, USA

Interferon regulatory factors constitute a family of transcriptional activators and repressors involved in a large number of vital cellular processes. Interferon regulatory factor-3 [IRF-3] has been implicated in virus and double-stranded RNA mediated induction of IFNβ and RANTES, in DNA damage signaling, and in virus-induced apoptosis. With its critical role in these pathways, the activity of IRF-3 is tightly regulated in myriad ways. Here we describe novel regulation of IRF-3 at the level of RNA splicing. We show that an unprecedented dual utilization of a splice acceptor/donor site within the IRF-3 mRNA governs the production of two alternative splice isoforms.

Received April 24, 2000; revised version accepted September 29, 2000.

The interferon regulatory factor [IRF] family of proteins includes transcriptional activators and repressors involved in a large number of cellular responses. The pathways governed by IRFs include cellular growth control, resistance to bacterial infection, commitment to transformation by oncoproteins, T and B cell development, response to DNA damage, apoptosis, and response to virus infection (for reviews, see Nguyen et al. 1997; Harada et al. 1998; Mamane et al. 1999). One IRF family member, IRF-3, has mainly been implicated in virus and double-stranded RNA mediated induction of IFNβ and RANTES, in DNA damage signaling, and in virus-induced apoptosis. With its critical role in these pathways, the activity of IRF-3 is tightly regulated in myriad ways. Here we describe novel regulation of IRF-3 at the level of RNA splicing. We show that an unprecedented dual utilization of a splice acceptor/donor site within the IRF-3 mRNA governs the production of two alternative splice isoforms.

Received April 24, 2000; revised version accepted September 29, 2000.

The interferon regulatory factor [IRF] family of proteins includes transcriptional activators and repressors involved in a large number of cellular responses. The pathways governed by IRFs include cellular growth control, resistance to bacterial infection, commitment to transformation by oncoproteins, T and B cell development, response to DNA damage, apoptosis, and response to virus infection. IRF-3, one of the IRF family members, has mainly been implicated in virus and double-stranded RNA mediated induction of IFNβ and RANTES, in DNA damage signaling, and in virus-induced apoptosis. With its critical role in these pathways, the activity of IRF-3 is tightly regulated in myriad ways. Here we describe novel regulation of IRF-3 at the level of RNA splicing. We show that an unprecedented dual utilization of a splice acceptor/donor site within the IRF-3 mRNA governs the production of two alternative splice isoforms.

Received April 24, 2000; revised version accepted September 29, 2000.

Results

Cloning and characterization of the IRF-3a splice form

In the course of our analysis of IRF-3 and the cDNA that encoded it, we identified an alternative cDNA that encodes an isoform, which we have called IRF-3a. IRF-3a, the 55 amino acid N terminus of IRF-3, is expressed ubiquitously in all tissues and cell lines tested, with variable ratios of IRF-3a to IRF-3 mRNA. We show that the organization of the alternative splice sites in the IRF-3 gene is novel and differs from patterns documented previously. We show that sequences downstream from the unusual splice junction are capable of binding members of the SR protein family, which can affect splice site selection.

[Key Words: IRF-3, splicing, SR proteins]

*Present address: Pfizer Inc., Discovery Technology Center, Cambridge, MA 02139, USA

E-MAIL peter_howley@hms.harvard.edu; FAX (617) 432-2882.

Article and publication are at www.genesdev.org/cgi/doi/10.1101/gad.813800.
stream from the end of exon 2, whereas the 5’ end of exon 3a maps right at the junction with exon 2 (see below). The exon encoding the IRF-3a-specific sequence is designated 3a (Figs. 1C,3A below).

IRF-3a and IRF-3 are ubiquitously expressed

To determine the relative patterns of expression of IRF-3 and IRF-3a in different cell types, an RNase protection assay (RPA) was used. A series of RPA probes spanning both the IRF-3a-specific and the common regions was designed to ensure the accurate detection of each of the IRF-3 mRNAs (Fig. 2A). Using these probes, the expression of IRF-3 and IRF-3a was assayed using RNA from normal human brain. Total RNA from HEC1B cells over-expressing IRF-3a was used as a positive control to define the pattern of protection by the three probes. Figure 2A shows that two main fragments of the expected sizes were protected by probe 1, with the upper band arising from the IRF-3a mRNA, and the lower one from the IRF-3 mRNA (lane 1). Reduction of the IRF-3a-specific region-protected probe 2 resulted in the change of migration of only the upper [IRF-3a] fragment [lane 2], whereas elimination of the unique region, and reduction in the size of the common region in probe 3, resulted in one band with faster migration [lane 3].

Probe 1 was further used to determine tissue distribution of the two mRNA isoforms. Figure 2B shows that both IRF-3 and IRF-3a are expressed ubiquitously, although the amounts of the transcripts vary in different tissue types and cell lines (see also Fig. 3C). More importantly, the levels of IRF-3a, in relation to that of IRF-3, vary over a greater than sevenfold range across the panel, with the highest ratio of expression found in the brain.

IRF-3a is generated by alternative splicing of IRF-3 pre-mRNA

To map the chromosomal location of the IRF-3a-specific sequence, a lambda phage containing an IRF-3 genomic clone was directly sequenced using primers hybridizing to the sequences in IRF-3 exon 2 and to sequences unique to IRF-3a. The IRF-3a initiator ATG was found to lie 172 nucleotides downstream from the 3’ end of exon 2 (Fig. 3A). To determine whether IRF-3a arises from the same precursor RNA as IRF-3 by alternative splicing, PCR was performed on a HeLa cDNA library using a sense primer in the noncoding exon 1 (bases 28–48) and an antisense IRF-3a-specific primer (bases 57–34). Sequencing of the cloned 295 bp PCR fragment revealed that the IRF-3a mRNA contains the entire exon 1 juxtaposed to the sequence immediately downstream from exon 2. These data imply that the IRF-3a-specific message is produced by splicing from the 3’ end of exon 1 to the 3’ end of exon 2 (Fig. 3B).

To verify the IRF-3a-specific splicing pattern, the

---

**Figure 1.** IRF-3a unique N-terminal sequence and genomic organization. (A) Schematic representation of the IRF-3 and IRF-3a proteins. Black box designates the novel 20 amino acids encoded by IRF-3a-specific exon. (B) Novel nucleotide and amino acid sequence comprising IRF-3 unique region. (C) Intron–exon borders for IRF-3 gene designated by Lowther and coworkers (1999). The IRF-3a-specific exon is positioned between exons designated 2 and 3.

---

**Figure 2.** IRF-3a is generated by alternative splicing. (A) Chromosomal location of the IRF-3a-specific sequence. Open boxes correspond to exon assignments [Lowther et al. 1999]. Exonic sequences are capitalized; splice donor and acceptor sites are bolded and underlined. (B) Schematic of the exon–intron structure of the 5’ part of the IRF-3 gene and of the IRF-3 and IRF-3a-specific splicing patterns. (C) RNase protection analysis of the IRF-3a-specific splicing pattern. PCR-amplified fragment of IRF-3a cDNA was used to generate an antisense riboprobe, which was hybridized with the total RNA from a panel of cell types. Lines represent vector sequences remaining in the probe. The numbers correspond to the sizes of the respective fragments. Schematic to the right of the blot shows the inferred structure of the protected fragments.
SR proteins might bias splice site selection in the IRF-3 pre-mRNA

The observation that the mRNAs for IRF-3 and IRF-3a are generated by mutually exclusive mechanisms utilizing the same sequence, raised the possibility that production of IRF-3a is regulated at the level of RNA splicing. Furthermore, the sequence at the junction of exons 2 and 3a conforms much better to a consensus for a splice donor than for a splice acceptor. A mechanism for up-regulating the use of weak alternative 3' splice sites with splice acceptor sequences far from the consensus, involves SR splicing factors acting through enhancer sequences in the immediate downstream exons (Chabot 1996; Manley and Tacke 1996; Cooper and Mattox 1997; Blencowe 2000). To address the possibility that SR proteins might recognize sequences in the 5' end of exon 3a, electrophoretic mobility shift assay (EMSA), using sense RNA transcripts spanning the region of interest, was carried out. Part of the genomic sequence encompassing half of exon 2 and the entire exon 3a was cloned downstream from a T3 promoter. The plasmid was linearized at various sites within the 3a exon, and radiolabeled RNA products of various lengths were synthesized by in vitro transcription (Fig. 4A). These RNA probes were then incubated either in the absence or presence of HEC1B cell nuclear lysate, and the indicated antibodies and complexes were resolved by nondenaturing acrylamide gel electrophoresis. Figure 4B shows that a distinct complex formed on the longer sense template RNA, which could be specifically supershifted using an antibody (α-SR) that recognizes all of the SR protein family members, but was not observed using the antibody to a specific SR protein, SF-2, or a control antibody. To determine which SR proteins are capable of binding this RNA sequence, an RNA pull-down assay was performed. Biotinylated RNAs were synthesized and incubated with the nuclear extracts under the conditions of the gel shift assay. RNA protein complexes were subsequently isolated using streptavidin-conjugated magnetic beads, and bound proteins resolved on an SDS gel. Western analysis was then performed using the anti-SR antibody. Figure 4C shows that the longer RNA template specifically brought down two proteins identified by the α-SR antibody with mobilities of ∼40 and 55 kD, possibly corresponding to SRp40 and SRp55. Significantly, this interaction was specific for the sense message, as no SR protein binding was detected using an antisense RNA. Thus, a subset of the SR family of splicing factors, likely including SRp40 and SRp55, is capable of binding pre-mRNA arising from the IRF-3 gene within 150 nucleotides downstream from the alternative splice site.

To determine if the SR proteins are able to shift the balance between the two alternative processing pathways, splicing patterns of synthetic IRF-3 minigene constructs (Fig. 5A) were analyzed in HeLa cells transfected with expression plasmids for various SR protein family members. Figures 5B and 5C show that coexpression of SRp40 and SRp55 led to an increase in the ratio of IRF-3a to IRF-3-specific splicing products. This effect was de-
dependent on the presence of the SR protein-binding site in the RNA (cf. relative ratios for construct A, open boxes, with those for construct B, hatched boxes in 5A). In addition, SRp75 strongly affected the splice site choice. However, its activity was independent of the identified SR binding domain in the IRF-3a exon and is likely to be governed by additional regulatory elements. The data presented in Figure 5 represent a single experiment. However, effects of comparable magnitude were seen in an independent repeat of this experiment.

Discussion

This study describes an alternatively spliced isoform of IRF-3 and suggests that alternative splicing of IRF-3 may provide an additional level of regulation of its multifarious actions in different cellular pathways. Alternative splicing has been described for a variety of genes, particularly for those encoding transcription factors or those involved in specific aspects of development and cellular proliferation (Lopez 1995, 1998; Smith and Valcarcel 2000). Regulation of transcription factors by alternative splicing provides the potential for the generation of protein isoforms with altered DNA binding specificity, antagonistic transcription effector potential, and/or the potential to affect protein–protein interactions within large transcriptional complexes. Alternative splicing has already been described for several of the other IRF family members (Harada et al. 1994; Zhang and Pagano 1997). For regulation of IRF-3, the mechanism of splice site selection, however, appears to be unprecedented. Our analyses revealed that a single site at the end of IRF-3-specific exon 2 serves both as a splice donor in the formation of the IRF-3 message and as a splice acceptor in exclusion of exon 2 and generation of the IRF-3a message. Sequences at 5′ and 3′ splice sites usually include GU and AG at the beginning and end of the intron, as well as AG and GU at the end and beginning of the flanking exons. Thus, an AGGU sequence has the potential to serve as both 5′ and 3′ splice site. Indeed, this potential has been documented with an artificial minigene construct (Zandberg et al. 1995). However, to our knowledge such a combined splice site has not yet been observed for any natural cellular or viral gene.
Alternative splicing usually involves competition between potential splice sites. The choice of a particular site can be determined either by a strong match to the consensus sequence or by assistance of transacting factors. In particular, the SR family of splicing factors has been implicated in splice site selection. Purine-rich splicing enhancers usually lie within optional exons and facilitate splicing of the upstream intron. SR proteins appear to be involved in the function of these enhancer sequences (for reviews, see Chabot 1996; Manley and Tacke 1996; Cooper and Mattox 1997, Blencowe 2000; Smith and Valcarcel 2000). Our data indicate that a G-rich region in exon 3a, which is located between 100 and 150 nucleotides downstream from the regulated splice site, is capable of binding a subset of the SR proteins in vitro and directing splice site selection by these SR proteins in vivo. Thus, despite the fact that the site at the junction of exons 2 and 3a in the IRF-3 gene appears to have a much stronger match to the consensus for the splice donor than for the splice acceptor, SR family members have the potential to shift the balance in favor of the IRF-3a message. Given that various SR proteins, as well as their known kinase regulators, are expressed at different levels in different tissues (Zahler et al. 1993; Snow et al. 1997, Stojdl and Bell 1999), and that their activities can be cell-cycle regulated (Güll et al. 1994) and signal-induced (Screaton et al. 1995; Lynch and Weiss 2000), the levels of the IRF-3a message could vary dramatically among various cell types and under different physiologic conditions. In fact, different ratios of IRF-3a to IRF-3 messages were observed across the panel of cell lines and tissue types (Fig. 3).

It is noteworthy that the IRF-3a-specific products predominated in the in vivo splicing experiment with the minigene constructs. This demonstrates that despite a dissimilarity with the consensus sequence, the exon 2/3a junction can serve as an effective splice acceptor competing with the upstream acceptor site at the beginning of exon 2. In the context of the full-length IRF-3 pre-mRNA, the competition between the assembly of the spliceosome at the exon 1 and exon 3a pair versus the one at the exon 2 and exon 3 pair, may determine whether the unusual junction is used as a donor or acceptor in splicing. The availability of the exon 2 and exon 3 pair will depend on the relative rates of transcriptional elongation to synthesize the acceptor site at exon 3 for the junction to serve as a donor, versus assembly of the splicing machinery at the already available exon 1 and exon 3a pair. It has been shown that there can be cotranscriptional kinetic competition between alternative splicing pathways (Roberts et al. 1998). Thus, in addition to the activity of the SR proteins, factors that regulate transcriptional elongation/pausing rates, might affect the level of production of IRF-3a-specific message.

Our results suggest that the splicing of the IRF-3/IRF-3a transcripts may be regulated in a tissue-specific manner. Furthermore, our analysis of IRF-3a function led to characterization of its dominant negative effect on IRF-3-dependent IFNβ induction (AYK, LVR, and PMH, in prep.). We postulate that the relative levels of IRF-3a to IRF-3 in a given cell type may dictate the extent of IRF-3 activity in all or a subset of the IRF-3 responsive pathways. For example, virus-induced IFNβ production is likely attenuated in certain cell types due to the toxic effects of IFNβ exposure, and regulated splicing in favor of IRF-3a-specific mRNA would contribute to this attenuation.

Thus, an unprecedented alternative splicing mechanism of the IRF-3 gene-encoded transcript leads to production of two isoforms. Our results show that expression of IRF-3a is ubiquitous, but that its levels, compared to those of IRF-3, vary in a tissue-specific manner. Furthermore, our data suggest that the alternative splicing for IRF-3a expression might be further regulated by the SR proteins, as well as by conditions regulating transcriptional elongation. Because the SR proteins are known to be regulated in a cell cycle and stimuli-dependent manner, expression of IRF-3a might be further regulated under special conditions that remain to be identified.

Materials and methods

Isolation of human genomic clone of IRF-3

A lambda FIX II human genomic library (Stratagene) was screened using a 32P-labeled probe corresponding to the first 700 nucleotides of human IRF-3a. Five genomic recombinant clones containing IRF-3 were isolated after screening 6 × 105 plaques. The phage DNA from two clones was purified to homogeneity. PCR was performed using IRF-3- and 3a-specific oligonucleotides. Amplified fragments were subcloned and sequenced.

RNase protection

Total RNA was isolated using TRIzol reagent (GIBCO/BRL). To generate the IRF-3/3a antisense riboprobes, EcoRI-BstYI fragment from IRF-3a pcDNA3 plasmid was subcloned into the EcoRI-BamHI sites of the pBS KS vector. The latter construct was linearized with HindIII for probe 1, with PstI for probe 2, and with Ndel for probe 3. The linearized constructs were in vitro transcribed with T7 RNA polymerase (Promega). Amplified fragments were subcloned into pBS KS vector digested with PstI and BamHI. The resulting construct was linearized with EcoRI and in vitro transcribed with T7 RNA polymerase.

The assays were performed using RPA II or HybSpeed RPA kits from Ambion (Austin, TX).

Electrophoretic mobility shift assays and RNA pull-down assay

For RNA EMSA, RNA probes were in vitro transcribed with T3 RNA polymerase in the presence of 5 µl of 32P-UTP (800 Ci/mmol), 10 mCi/mL, NEN LifeSciences) and 0.1 mM cold UTP. The full-length probes were gel purified, and 20,000 cpm were used per reaction. The gel shift reaction was performed in 10 µL containing 20–30 µg of HEC 1B cell nuclear lysate in the presence of 10 mM Tris-HCl (pH 7.5), 5 mM (CH3COO)2Mg, 100 mM CH3COOK, 2mM DTT, 0.1 mM spermine, 0.1 mg/mL BSA, 5% glycerol, and 0.4 U RNasin (Promega). Added to this to reduce nonspecific binding were 0.2 µg Escherichia coli tRNA, 0.1 µg yeast total RNA, and 5 µg heparin. After incubation at room temperature for 15 min, the reaction was resolved on a 4% acrylamide : bis 5% glycerol 0.5X TBE gel at 200 V at 4°C. For supershift experiments, 1 µg of the corresponding antibodies was added to the reaction. The antiSF-2 antibody was a generous gift of Dr. Kline (Cold Spring Harbor Laboratory, NY). The antiSR antibody (1H4) was from Zymed.

For RNA pull-down experiments, the above-mentioned templates were synthesized in the presence of 0.2 mM biotin-16-UTP [Roche Biochemicals] and 0.3 mM cold UTP. The probes were gel-purified, and 100 pg of RNA were incubated with 20–30 µg of HEC 1B cell nuclear lysate under the gel-shift conditions. After incubation, 10 µL of M-280 streptavidin magnetic beads (Dynal), pre-equilibrated in the binding buffer, were added to the reaction. The samples were then incubated on ice for 15 min with intermittent gentle vortexing, and RNA-protein complexes were isolated using a magnetic stand (Dynal). After two washes with the bind-
ing buffer, the beads were resuspended in a 1x SDS buffer, and bound proteins were resolved on a 10% SDS gel and detected by Western analysis using α-SR1 H4 antibody.

**In vivo splicing reactions**

Synthetic minigenes constructs were generated from the genomic IRF-3 clone by PCR using the primers hybridizing in exons 1 and 3a. The sequences of the primers were as follows: exons1, CTGACTGTTTGAGAGCTCTAG; exon 3a probe A, GTAACCCTGACCTCCAC; exon 3a probe B, CAGCTCCGGCTTTCAAG. PCR products were initially cloned into the PCR-Blunt II vector [Invitrogen], and then recloned into pcDNA3 using NotI–KpnI digest. The pcDNA3 constructs were cotransfected with various SR protein expression vectors into HeLa cells using Lipofectamine2000 reagent [GIBCO BRL]. Twenty-four hours after transfection, cDNA corresponding to the spliced products was synthesized from 3 µg of total RNA using AMV-RT (GIBCO BRL), and 40% of the product used for a 25 cycle PCR using Pfx polymerase (GIBCO BRL). The primers used in RT and PCR steps were derived from the sequences of the pcDNA3 vector.

**Acknowledgments**

We thank Charles Ro for expert technical assistance. We are grateful to Dr. Adrian Krainer for antiSF-2 antibody, to Dr. Robert Lafyatis for the SR protein expression vectors, and to Jeffrey Sklar for the human genomic library. Our appreciation to Dr. Paula Pitha for sharing reagents. We thank Dr. Juan Valcarcel for helpful discussion. L.V.R. was supported by fellowship grants 5 F32 AI09167-02 from the NIH and from Aid for Cancer Research. A.Y.K. is a Howard Hughes Medical Institute Predoctoral Fellow. This research was supported by NIH grant PO1 AI 42257 to P.M.H.

The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked as pro.

**References**

Baeuerle, P.A. and Baltimore, D. 1996. NF-κB/H9260 of page charges. This article must therefore be hereby marked as pro.

This research was supported by NIH grant PO1 AI 42257 to P.M.H. Thank Dr. Juan Valcarcel for helpful discussion. L.V.R. was supported by NIH grant PO1 AI 42257 to P.M.H.

The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 USC section 1734 solely to indicate this fact.

**References**

Baerle, P.A. and Baltimore, D. 1996. NF-κB: Ten years after. *Cell* 87: 13–20.

Blencowe, B.J. 2000. Exonic splicing enhancers: Mechanism of action, diversity and role in human genetic diseases. *Trends Biochem. Sci.* 25: 106–110.

Chabot, B. 1996. Directing alternative splicing: Cast and scenarios. *Trends Genet.* 12: 472–478.

Cooper, T.A. and Mattox, W. 1997. The regulation of splice-site selection, and its role in human disease. *Annu. Rev. Genet.* 41: 259–266.

Gui, J.F., Lane, W.S., and Fu, X.D. 1994. A serine kinase regulates intracellular localization of splicing factors in the cell cycle. *Nature* 369: 678–682.

Harada, H., Kondo, T., Ogawa, S., Tamura, T., Kitagawa, M., Tanaka, N., Lamphier, M.S., Hirai, H., and Taniguchi, T. 1994. Accelerated exon skipping of IRF-1 mRNA in human myelodysplasia/leukemia: A possible mechanism of tumor suppressor inactivation. *Oncogene* 9: 3313–3320.

Harada, H., Taniguchi, T., and Tanaka, N. 1998. The role of interferon regulatory factors in the interferon system and cell growth control. *Biochimie* 80: 641–650.

Heylbroeck, C., Balachandran, S., Servant, M.J., DeLuca, C., Barber, G.N., Lin R., Hiscott, J. 1999. The IRF-3 transcription factor mediates Sendai virus-induced apoptosis. *J. Virol.* 73: 3781–3792.

Kim, T., Kim, T.Y., Song, Y.H., Min, I.M., Yim, J., and Kim, T.K. 1999. Activation of interferon regulatory factor 3 in response to DNA-damaging agents. *J. Biol. Chem.* 274: 30686–30689.

Lin, R., Heylbroeck, C., Pitha, P.M., and Hiscott, J. 1998. Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. *Mol. Cell. Biol.* 18: 2986–2996.

Lin, R., Heylbroeck, C., Genin, P., Pitha, P.M., and Hiscott, J. 1999. Essential role of interferon regulatory factor 3 in direct activation of RANTEs chemokine transcription. *Mol. Cell. Biol.* 19: 959–966.

Lopez, A.J. 1995. Developmental role of transcription factor isoforms generated by alternative splicing. *Dev. Biol.* 172: 396–411.

———. 1998. Alternative splicing of pre-mRNA: Developmental consequences and mechanisms of regulation. *Annu. Rev. Genet.* 32: 279–305.

Lowther, W.J., Moore, P.A., Carter, K.C., and Pitha, P.M. 1999. Cloning and functional analysis of the human IRF-3 promoter. *DNA Cell Biol.* 18: 685–692.

Lynch, K.W. and Weiss, A. 2000. A model system for activation-induced alternative splicing of CD45 pre-mRNA in T cells implicates protein kinase C and Ras. *Mol. Cell. Biol.* 20: 70–80.

Mamane, Y., Heylbroeck, C., Genin, P., Aljart, E., Servant, M.J., LePage, C., DeLuca, C., Kwon, H., Lin, R., and Hiscott, J. 1999. Interferon regulatory factors: The next generation. *Gene* 237: 1–14.

Manley, J.L. and Tacke, R. 1996. SR proteins and splicing control. *Genes & Dev.* 10: 1569–1579.

Navarro, L., Mowen, K., Rodems, S., Weaver, B., Reich, N., Spector, D., and David, M. 1998. Cytomegalovirus activates interferon immediate-early response gene expression and an interferon regulatory factor 3-containing interferon-stimulated response element-binding complex. *Mol. Cell. Biol.* 18: 3796–3802.

Nguyen, H., Hiscott, J., and Pitha, P.M. 1997. The growing family of interferon regulatory factors. *Cytokine Growth Factor Rev.* 8: 293–312.

Roberts, G.C., Gooding, C., Mak, H.Y., Proudfait, N.J., and Smith, C.W.J. 1998. Co-transactional commitment to alternative splice site selection. *Nucleic Acids Res.* 26: 5568–5572.

Ronco, L.V., Karpova, A.Y., Vidal, M., and Howley, P.M. 1998. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. *Genes & Dev.* 12: 2061–2072.

Sreecat, G.R., Caceras, J.F., Mayeda, A., Bell, M.V., Bleibanski, M., Jackson, D.G., Bell, J.I., and Kramer, A.R. 1995. Identification and characterization of three members of the human SR family of pre-mRNA splicing factors. *EMBO* J. 14: 4336–4349.

Smith, C.W.J. and Valcarcel, J. 2000 Alternative pre-mRNA splicing: The logic of combinatorial control. *Trends Biochem. Sci.* 25: 381–388.

Snow, B.E., Heng, H.H., Shi, X.M., Zhou, Y., Du, K., Taub, R., Tsui, L.C., and Mclnnes, R.R. 1997. Expression analysis and chromosomal assignment of the human SFRS5/SRp40 gene. *Genomics* 41: 165–170.

Stooli, D.F. and Bell, J.C. 1999. SR protein kinases: The splice of life. *Biochem. Biophys. Res. Commun.* 277: 293–298.

Watelelet, M., Lin, C.H., Parekh, B., Ronco, L.V., Howley, P.M., and Maniatis, T. 1998. Virus infection induces the assembly of coordinately activated transcription factors on the IFN-β enhancer in vivo. *Mol. Cell.* 1: 507–518.

Weaver, B.K., Prasanna Kumar, K., and Reich, N.C. 1998. Interferon regulatory factor 3 and CREB-binding protein/p300 are subunits of double-stranded RNA-activated transcription factor DRAF1. *Mol. Cell. Biol.* 18: 1359–1366.

Yoneyma, M., Suhara, W., Fukushima, Y., Fukuda, M., Nishida, E., and Fujita, T. 1998. Direct triggering of the type 1 interferon system by virus infection: Activation of two transcription factor complex containing IRF-3 and CBP/p300. *EMBO* J. 17: 1087–1095.

Zahler, A.M., Neugebauer, K.M., Lane, W.S., and Roth, M.B. 1993. Distinct functions of SR proteins in alternative pre-mRNA splicing. *Science* 260: 219–222.

Zandberg, H., Moen, T.C., and Baas, P.D. 1995. Cooperation of Sp1 and Sp3 processing sites as well as exon and exons sequences in calcinonin exon recognition. *Nucleic Acids Res.* 23: 248–255.

Zhang, L. and Pagano, J.S. 1997. IRF-7, a new interferon regulatory factor associated with Epstein-Barr virus latency. *Mol. Cell. Biol.* 17: 5748–5757.

———. 1998. Alternative splicing of pre-mRNA: Developmental consequences and mechanisms of regulation. *Annu. Rev. Genet.* 32: 279–